display
Grünwald (dpa) - A high demand for products to strengthen the immune system drove the drug company Dermapharm in the Corona year 2020.
Thanks to the takeover of the allergy specialist Allergopharma, sales and operating profit in day-to-day business increased by around 13 percent compared to the previous year, as the SDax-listed company announced on Tuesday in Grünwald on the basis of preliminary figures.
For the current year, CEO Hans-Georg Feldmeier is building on the production of the corona vaccine for the Mainz company Biontech.
After the start of production in Brehna in October, production should also start in Reinbek near Hamburg in May.
In the past year, Dermapharm increased sales by 13 percent to 794 million euros.
Earnings before interest, taxes, depreciation and amortization (Ebitda) adjusted for special items increased just as strongly to 201 million euros.
Including special effects, the Ebitda grew by nine percent to 185 million euros.
The company plans to publish the full balance sheet and a forecast for 2021 on April 13th.
© dpa-infocom, dpa: 210330-99-23060 / 2